KRP-205
Focal Segmental Glomerulosclerosis (FSGS)
Phase IIActive
Key Facts
Indication
Focal Segmental Glomerulosclerosis (FSGS)
Phase
Phase II
Status
Active
Company
About Kissei Pharmaceutical
Kissei Pharmaceutical's mission is to contribute to global healthcare by developing and providing innovative, high-quality pharmaceutical products. The company has achieved a strong market position in Japan through its established expertise in urology and nephrology, supported by a portfolio of marketed products and a promising late-stage pipeline. Its strategy centers on deepening its specialization in core therapeutic areas while expanding its global footprint through strategic in-licensing and co-development partnerships. With a market capitalization of approximately $193.58 billion, Kissei possesses the financial strength to advance its R&D ambitions and pursue strategic opportunities.
View full company profileTherapeutic Areas
Other Focal Segmental Glomerulosclerosis (FSGS) Drugs
| Drug | Company | Phase |
|---|---|---|
| DMX-200 | Amicus Therapeutics | Phase 3 |
| Sparsentan | Travere Therapeutics | Phase 3 |
| Voclosporin | Aurinia Pharmaceuticals | Phase 2 |